Cat. No. 3366
Chemical Name: 7-Bromo-2-(4-hydroxyphenyl)-1,3-ben
Biological ActivitySelective ERβ receptor agonist that displays 68-fold selectivity over ERα (EC50 values are 2 and 155 nM for ERβ and ERα respectively). Displays antianxiolytic and antidepressive effects in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Clipperton et al (2008) Differential effects of estrogen receptor alpha and beta specific agonists on social learning of food preferences in female mice. Neuropsychopharmacology 33 2362. PMID: 18004284.
Hughes et al (2008) WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 54 1136. PMID: 18423777.
Malamas et al (2004) Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J.Med.Chem. 47 5021. PMID: 15456246.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for WAY 200070 include:
Sellers et al (2015) Rapid modulation of synaptogenesis and spinogenesis by 17β-estradiol in primary cortical neurons. Front Cell Neurosci 9 137. PMID: 25926772.
Cao et al (2012) Estrogen receptor β activation is antinociceptive in a model of visceral pain in the rat. J Pain 13 685. PMID: 22698981.
Do you know of a great paper that uses WAY 200070 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: WAY 200070, supplier, Selective, ERβ, ERbeta, agonists, estrogen, receptors, WAY200070, Tocris Bioscience, Estrogen and Related Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonistIP7e
Potent Nurr1 activator
October 30 - November 3, 2016
Boston, MA, USA